A New Alzheimer’s Blood Test Approved in the U.S.—But Canada Must Catch Up
The U.S. Food and Drug Administration (FDA) approved a groundbreaking new blood test designed to assist in the diagnosis of Alzheimer’s disease.
Developed by Roche, the Elecsys pTau181 test measures levels of a specific molecule—a phosphorylated form of the tau protein—in the blood.
Tau is one of two hallmark proteins, alongside amyloid, that misfold and accumulate in the brains of people with Alzheimer’s and related dementias. The buildup of these proteins disrupts brain cell communication, leading to the cognitive and behavioral symptoms characteristic of Alzheimer’s.
Already Authorized in Europe—But Not Yet in Canada
The test was first authorized in Europe earlier this year and is now approved in both of the world’s largest pharmaceutical markets—the U.S. and the European Union. However, Canada has yet to approve this test, meaning Canadian patients and clinicians remain without access to this potentially transformative early diagnostic tool.
This is particularly concerning because Alzheimer’s and other dementias are rising rapidly in Canada:
- More than 600,000 Canadians live with dementia today.
- This number is projected to double by 2050.
- The annual economic burden exceeds $10 billion in healthcare costs and lost productivity.
How Does the Elecsys pTau181 Test Work?
Elecsys pTau181 detects a form of the tau protein that has a phosphate group attached—a biomarker that correlates with Alzheimer’s pathology. Elevated levels of this molecule suggest the presence of amyloid plaques and tau tangles in the brain.
Previously, confirming an Alzheimer’s diagnosis required invasive and costly tests such as:
- Positron Emission Tomography (PET) scans
- Cerebrospinal fluid (CSF) analysis via lumbar puncture
The new blood test offers a less invasive, lower-cost alternative for initial screening—particularly at the primary care level, where most patients first present with memory concerns.
Why Now?
Until recently, confirming Alzheimer’s disease did little to change treatment plans—there were no effective drugs that could alter disease progression.
But that changed with the approval of new monoclonal antibody therapies (such as lecanemab and donanemab) that target amyloid buildup.
These treatments work best when given early in the disease process, so having a fast, accessible blood test to identify eligible patients is crucial.
Accuracy and Limitations
The Elecsys pTau181 test shows a negative predictive value of 97.9%—meaning it is highly accurate at ruling out Alzheimer’s in patients who test negative.
However, up to 30% of patients may fall into a “gray zone” where biomarker levels are inconclusive.
This underscores the need for specialist follow-up and confirmatory imaging or CSF testing in positive or borderline cases.
Proceed with Caution
Experts caution that these tests should not be used casually or for self-screening. Their positive predictive value is modest, leading to a risk of false positives—especially in people without cognitive symptoms.
Misinterpretation of results could lead to unnecessary anxiety or inappropriate treatment referrals.
The Case for Canadian Approval
Canadian researchers, clinicians, and policymakers must act quickly to evaluate and approve such diagnostic tools.
Early detection can:
- Improve patient outcomes by initiating treatment sooner.
- Allow families to plan and access support earlier.
- Reduce the long-term economic and social burden of dementia care.
The Elecsys pTau181 test represents a critical step toward a new model of Alzheimer’s care—one that empowers primary care providers to identify risk earlier, with greater precision and compassion.
At Orleans Family Health Clinic (OFHC)
Our physicians remain committed to evidence-based dementia care and early screening for cognitive disorders.
We encourage families with memory or behavioral concerns to book an assessment—the earlier the evaluation, the better the options for treatment and support.
Stay Connected with Orleans Family Health Clinic!
If you found this article helpful, don’t forget to like, share, and Follow to stay up to date on our latest health tips, updates, and wellness advice.
And follow us on social media
Disclaimer: The medical information on this site is provided as an information resource only and is not to be used or relied on for any diagnostic or treatment purposes. This information does not substitute for professional diagnosis and treatment. Please do not initiate, modify, or discontinue any treatment, medication, or supplement solely based on this information. Always seek the advice of your healthcare provider first. Full Disclaimer.
